Eton Pharmaceuticals price target raised to $11 from $9 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Eton Pharmaceuticals to $11 from $9 and keeps a Buy rating on the shares after the company entered into an all-cash asset purchase agreement with Ipsen to acquire Increlex. The firm says Increlex adds to Eton’s pediatric endocrinology portfolio. Increlex being a pediatric endocrinology therapy could potentially be synergistic to the rest of the current commercial portfolio and provide sustained revenue growth in 2025 and beyond, the analyst tells investors in a research note.